Northstar brain therapy fails late-stage trial

Northstar Neuroscience says that a brain stimulation therapy intended to improve hand and arm function in stroke victims flunked a late-stage trial. Northstar's treatment uses electrical stimulation to the brain, but it failed to improve limb function by 20 percent, the primary goal of the trial. Seattle-based Northstar says it is unlikely that the data warrants FDA approval for that, but adds that it still has potential for other conditions, including depression and tinnitus.

- see this release
- check out the AFX report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.